Compugen Ltd. (NASDAQ: CGEN) today reported financial results for the second quarter ending June 30, 2014.
Dr. Anat Cohen-Dayag, Compugen’s President and CEO, stated, "During the first six months of this year, our R&D efforts focused primarily on advancing product candidates in our Pipeline Program, diversifying the pipeline with additional target candidates for antibody-based therapy, and extending our capabilities to enable the validation and development of multiple product candidates in parallel. Product candidates added to the Pipeline Program since late last year include two additional B7/CD28-like checkpoint candidates that increased the total number of such discoveries by Compugen to eleven, five target candidates for antibody-drug conjugate cancer therapy, and four immune-modulatory targets candidates distinct from the B7/CD28 family of proteins.”
Dr. Cohen-Dayag continued, “Following these latest additions, the oncology arm of our Pipeline Program now includes early stage target candidates representing three different approaches for antibody-based cancer treatment, all based on Compugen-discovered targets. We believe that this achievement, which is unique in our industry, provides an excellent example of the value of Compugen’s long-term investment in establishing its broadly applicable predictive discovery infrastructure.”
Dr. Cohen-Dayag concluded, "We are already beginning to see an acceleration of positive experimental results with respect to our Pipeline Program candidates. This, combined with the resulting increase in both industry recognition of our discovery capabilities and interest in our pipeline candidates, provides us with even greater confidence of achieving our short-term objectives and longer-term goals.”
Revenues for the second quarter of 2014 and six months ending June 30, 2014 were $2.0 million and $4.1 million respectively, compared with $22,000 and $184,000 for the comparable periods in 2013. These substantial increases from the prior year periods resulted primarily from a milestone payment and the recognizable portions of a non-refundable upfront payment in accordance with US GAAP revenue recognition accounting, in each case pursuant to the August 2013 collaboration and license agreement with Bayer Pharma AG.
Cost of revenues for the second quarter of 2014 and the six months ending June 30, 2014 were $0.9 million and $1.6 million respectively, compared with $84,000 and $234,000 for the comparable periods in 2013. These increases are largely the result of increased research and development expenses attributed to our current collaborations.
Research and development expenses, net, for the second quarter of 2014 and the six months ending June 30, 2014 were $3.1 million and $6.3 million respectively, compared with $3.4 million and $6.2 million for the comparable periods in 2013. Research and development expenses do not include expenses incurred in support of current collaborations which, as noted above, are accounted for as cost of revenues.
Compugen’s net loss for the second quarter of 2014 was $2.3 million (after reflecting non-cash stock-based compensation of $0.7 million), or $0.05 per basic share, compared with a net loss of $3.0 million (after reflecting non-cash stock-based compensation of $0.7 million), or $0.08 per basic share, for the comparable period in 2013. Compugen’s net loss for the first six months of 2014 was $4.2 million (after reflecting non-cash stock-based compensation of $1.6 million), or $0.09 per basic share, compared with a net loss of $6.4 million (after reflecting non-cash stock-based compensation of $1.4 million), or $0.17 per basic share, for the comparable period in 2013. The reductions in net loss for the second quarter and the first six months of 2014, compared with the comparable periods in 2013, were attributable to increases in revenues recognized for the quarter and the first six months, compared with the comparable periods in 2013, partially off-set by increased corporate expenses for such periods, primarily relating to research and development.
As of June 30, 2014 and December 31, 2013, the liability related to the "Research and development funding arrangements" amounted to $13.1 million and $13.2 million respectively, in each case solely relating to the accounting for the Baize research and development funding arrangements signed in December 2011 and December 2010, as amended. These noncash liability balances, which increase or decrease based on changes in the market value of Compugen ordinary shares, are primarily related to the estimated fair values of the embedded derivative instruments resulting from the right of the investor, under the amended agreement, to waive its right to receive potential future payments in exchange for Compugen ordinary shares.
As of June 30, 2014, cash, cash equivalents and short-term bank deposits totaled $113.3 million compared with $46.8 million at December 31, 2013. This increase of $66.5 million compared with December 31, 2013 resulted primarily from net proceeds of $67.0 million from the Company's underwritten public offering of ordinary shares completed in March 2014. With respect to calendar year 2014, Compugen has budgeted total cash expenditures (without taking into consideration actual to date or potential additional cash receipts) of approximately $24 million.
Conference Call and Webcast Information
Compugen will hold a
conference call to discuss its second quarter 2014 results today, August
6, 2014 at 10:00 a.m. EDT. To access the conference call, please dial
1-888-281-1167 from the US or +972-3-918-0610 internationally. The call
will also be available via live webcast located at the following link.
A replay of the conference call will be available approximately two
hours after the completion of the live conference call. To access the
replay, please dial 1-877-456-0009 from the US or +972-3-925-5925
internationally. The replay will be available through August 8, 2014.
About Compugen
Compugen is a leading drug discovery company
focused on therapeutic proteins and monoclonal antibodies to address
important unmet needs in the fields of immunology and oncology. The
Company utilizes a broad and continuously growing integrated
infrastructure of proprietary scientific understandings and predictive
platforms, algorithms, machine learning systems and other computational
biology capabilities for the in silico (by computer)
prediction and selection of product candidates, which are then advanced
in its Pipeline Program. The Company's business model includes
collaborations covering the further development and commercialization of
product candidates at various stages from its Pipeline Program and
various forms of research and discovery agreements, in both cases
providing Compugen with potential milestone payments and royalties on
product sales or other forms of revenue sharing. Compugen’s wholly-owned
U.S. subsidiary located in South San Francisco is developing monoclonal
antibody therapeutic candidates against its novel drug targets. For
additional information, please visit Compugen's corporate website at www.cgen.com.
Forward-Looking Statement Disclaimer
This press release
contains “forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements related
to the Company’ short and long-term objectives, anticipated total cash
uses for 2014 and product candidates added to the Company’s Pipeline
Program, including, without limitation, B7/CD28 checkpoint proteins,
targets for antibody-drug conjugate cancer therapy and other
immune-modulatory targets. Forward-looking statements can be identified
by the use of terminology such as “may,” “expectations,”
“approximately,” “further” and “potential” and describe opinions about
future events. These forward-looking statements involve known and
unknown risks and uncertainties that may cause the actual results,
performance or achievements of Compugen to be materially different from
any future results, performance or achievements expressed or implied by
such forward-looking statements. Some of these risks and other factors
are discussed in the "Risk Factors" section of Compugen’s Annual Report
on Form 20-F for the year ended December 31, 2013 as filed with the
Securities and Exchange Commission, as well as other documents that may
be subsequently filed by Compugen from time to time with the Securities
and Exchange Commission. In addition, any forward-looking statements
represent Compugen’s views only as of the date of this release and
should not be relied upon as representing its views as of any subsequent
date. Compugen does not assume any obligation to update any
forward-looking statements unless required by law.
COMPUGEN LTD. | |||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||
(U.S. dollars in thousands, except for share and per-share amounts) | |||||||||
Three Months Ended | Six Months Ended | ||||||||
2014 | 2013 | 2014 | 2013 | ||||||
Revenues | 1,964 | 22 | 4,097 | 184 | |||||
Cost of revenues | 859 | 84 | 1,616 | 234 | |||||
Gross profit (loss) | 1,105 | (62) | 2,481 | (50) | |||||
Operating expenses | |||||||||
Research and development expenses, net | 3,074 | 3,437 | 6,316 | 6,176 | |||||
Marketing and business development expenses | 109 | 157 | 282 | 352 | |||||
General and administrative expenses | 1,240 | 1,063 | 2,512 | 2,105 | |||||
Total operating expenses | 4,423 | 4,657 | 9,110 | 8,633 | |||||
Operating loss | (3,318) | (4,719) | (6,629) | (8,683) | |||||
Financing income, net | 1,059 | 1,680 | 2,472 | 2,270 | |||||
Net loss before taxes | (2,259) | (3,039) | (4,157) | (6,413) | |||||
Taxes on income | (60) | - | (60) | - | |||||
Net loss | (2,319) | (3,039) | (4,217) | (6,413) | |||||
Basic net loss per ordinary share | (0.05) | (0.08) | (0.09) | (0.17) | |||||
Weighted average number of ordinary shares used in computing basic net loss per share | 48,462,334 | 38,204,202 | 45,970,766 | 37,746,520 | |||||
Diluted net loss per ordinary share | (0.07) | (0.09) | (0.09) | (0.18) | |||||
Weighted average number of ordinary shares used in computing diluted net loss per share | 49,796,012 | 40,221,504 | 45,970,766 | 39,140,651 | |||||
COMPUGEN LTD. | |||||
CONDENSED CONSOLIDATED BALANCE SHEETS DATA | |||||
(U.S. dollars, in thousands) | |||||
June 30, | December 31, | ||||
ASSETS | |||||
Current assets | |||||
Cash, cash equivalents and short-term bank deposits | 113,259 | 46,766 | |||
Investment in Evogene | 1,858 | 4,565 | |||
Trade receivable | 1,140 | - | |||
Other accounts receivable and prepaid expenses | 912 | 1,885 | |||
Total current assets | 117,169 | 53,216 | |||
Non-current investments | |||||
Severance pay fund | 2,256 | 2,129 | |||
Total non-current investments | 2,256 | 2,129 | |||
Non-current prepaid expenses | 107 | 158 | |||
Property and equipment, net | 2,009 | 1,208 | |||
Total assets | 121,541 | 56,711 | |||
LIABILITIES AND SHAREHOLDERS’ EQUITY | |||||
Current liabilities | |||||
Other accounts payable, accrued expenses and trade payables | 3,692 | 2,421 | |||
Deferred revenues | 3,121 | 5,318 | |||
Total current liabilities | 6,813 | 7,739 | |||
Non-current liabilities | |||||
Research and development funding arrangement | 13,074 | 13,189 | |||
Deferred revenues | 948 | 1,454 | |||
Accrued severance pay | 2,577 | 2,441 | |||
Total non-current liabilities | 16,599 | 17,084 | |||
Total shareholders’ equity | 98,129 | 31,888 | |||
Total liabilities and shareholders’ equity | 121,541 | 56,711 | |||
Contacts:
Tsipi Haitovsky, Global Media Liaison
+972-52-598-9892
tsipih@cgen.com